Literature DB >> 11437847

MIB-1 and p53 expression in radiotherapy-resistant T1aN0M0 glottic squamous cell carcinoma.

M Motamed1, A R Banerjee, P J Bradley, D Powe.   

Abstract

Radiotherapy of T1aN0M0 glottic carcinoma results in a local control rate of 80-94%. This homogenous group, which is the earliest recognisable invasive malignancy in the head and neck region, provides a 'unique model' for studying possible biological markers of radiosensitivity. p53 and MIB-1 were investigated as possible markers of radiosensitivity in such a group. In all, 107 patients with T1aN0M0 glottic squamous cell carcinoma treated with radiotherapy were identified. Cases not responsive to radiotherapy were compared with matched radiosensitive controls by immunohistochemistry using monoclonal primary antibodies to MIB-1 (n = 18; controls = 10) and p53 (n = 6; controls = 11). No significant difference in p53 expression was noted between the two groups (P = 0.73). A greater MIB-1 expression was found in the radiosensitive group but only a trend towards significance was observed (P = 0.06). MIB-1 is a potential marker of radiosensitivity. A larger multicentre study is required for a more definitive answer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437847     DOI: 10.1046/j.1365-2273.2001.00461.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  2 in total

1.  Standardised Ki-67 proliferation index assessment in early-stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy.

Authors:  Emiel Kop; Geertruida H de Bock; Maartje G Noordhuis; Lorian Slagter-Menkema; Bernard F A M van der Laan; Johannes A Langendijk; Ed Schuuring; Bert van der Vegt
Journal:  Clin Otolaryngol       Date:  2019-11-05       Impact factor: 2.597

2.  Biological tumor markers associated with local control after primary radiotherapy in laryngeal cancer: A systematic review.

Authors:  Maartje G Noordhuis; Emiel A Kop; Bert van der Vegt; Johannes A Langendijk; Bernard F A M van der Laan; Ed Schuuring; Geertruida H de Bock
Journal:  Clin Otolaryngol       Date:  2020-04-23       Impact factor: 2.597

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.